The antibody-drug conjugate market is picking up right where it left off in 2023 as Roche has made a potential $1 billion deal with China-based MediLink Therapeutics to develop a next-generation ADC in oncology, the Chinese biotech announced on Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,